By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on Biotechnology have been presented. According to news reporting out of Shandong, People's Republic of China, by NewsRx editors, research stated, "Gastric cancer is highly aggressive disease. Despite advances in diagnosis and therapy, the prognosis is still poor."
Our news journalists obtained a quote from the research from Shandong University, "Various genetic and molecular alterations are found in gastric cancer that underlies the malignant transformation of gastric mucosa during the multistep process of gastric cancer pathogenesis. The detailed mechanism of the gastric cancer development remains uncertain. In present study we investigated the potential role of stathmin1 gene in gastric cancer tumorigenesis and examined the usefulness of RNA interference (RNAi) targeting stathmin1 as a form of gastric cancer treatment. A lentiviral vector encoding a short hairpin RNA (shRNA) targeted against stathmin1 was constructed and transfected into the packaging cells HEK 293 T and the viral supernatant was collected to transfect MKN-45 cells. The transwell chemotaxis assay and the CCK-8 assay were used to measure migration and proliferation of tumor cells, respectively. Quantitative real-time PCR and western blotting were used to detect the expression levels of stathmin1. Lentivirus mediated RNAi effectively reduced stathmin1 expression in gastric cells. Significant decreases in stathmin1 mRNA and protein expression were detected in gastric cells carrying lentiviral stathmin-shRNA vector and also significantly inhibited the proliferation, migration in gastric cancer cells and tumorigenicity in Xenograft Animal Models. Our findings suggest that stathmin1 overexpression is common in gastric cancer and may play a role in its pathogenesis. Lentivirus mediated RNAi effectively reduced stathmin1 expression in gastric cells."
According to the news editors, the research concluded: "In summary, shRNA targeting of stathmin1 can effectively inhibits human gastric cancer cell growth in vivo and may be a potential therapeutic strategy for gastric cancer."
For more information on this research see: Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. Journal of Translational Medicine, 2013;11():1-9. Journal of Translational Medicine can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Journal of Translational Medicine - www.translational-medicine.com)
Our news journalists report that additional information may be obtained by contacting J. Akhtar, Shandong University, Dept. of Thorac Surg, Prov Hosp, Jinan 250021, Shandong, People's Republic of China. Additional authors for this research include Z. Wang, Z.P. Zhang and M.M. Bi (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Shandong, Genetics, Oncology, Therapeutics, Gastric Cancer, Gastroenterology, Cancer Gene Therapy, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC